The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: Results of a multicenter phase II clinical trial.
Raffit Hassan
No relevant relationships to disclose
Thierry Marie Jahan
Research Funding - Morphotek
Hedy Lee Kindler
Research Funding - Morphotek
Lyudmila Bazhenova
No relevant relationships to disclose
Martin Reck
No relevant relationships to disclose
Ira Pastan
No relevant relationships to disclose
Alison Ellis
Employment or Leadership Position - Morphotek
Penny Marie Fatato
Employment or Leadership Position - Morphotek
John Heyburn
Employment or Leadership Position - Morphotek
Charles Schweizer
Employment or Leadership Position - Morphotek
Jeff Parno
Consultant or Advisory Role - Morphotek
Bruce Wallin
Consultant or Advisory Role - Morphotek